Telix Pharmaceuticals Ltd Sustainability Reports

Telix Pharmaceuticals Limited is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. The company designs targeted radiation therapies and imaging agents primarily for prostate, kidney, and brain cancer applications.

Sector: Manufacturing

Country: Australia

Exchange: Australian Securities Exchange

LEI: 894500HTWOOGIHLLSB86

FIGI: BBG00HZHXWV5

15 reports from 2017 to 2025

• Telix Pharmaceuticals Ltd 2025 Annual Report
• Telix Pharmaceuticals Ltd 2024 Modern Slavery and Transparency in Supply Chain Statement
• Telix Pharmaceuticals Ltd 2024 Results Announcement for the Full Year Ended 31 December
• Telix Pharmaceuticals Ltd 2024 Sustainability Report
• Telix Pharmaceuticals Ltd 2023 Results Announcement